Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EWALL-PH-03 ponatinib vs imatinib plus chemotherapy in older adults with Philadelphia chromosome-positive acute lymphoblastic leukemia
2023-505330-95-01Phase 2Authorised
- Sponsor
- Cardiff University
- Start
- Jan 2025
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of ponatinib, imatinib and blinatumomab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Cardiff University. Primary endpoint: Molecular response after consolidation 2 or within 5 months. Planned start Jan 2025; status: authorised.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2023-505330-95-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505330-95-01.